Equities

Guangdong Marubi Biotechnology Co Ltd

  • Add to watchlist
  • Add to portfolio
  • Add an alert

Guangdong Marubi Biotechnology Co Ltd

Actions
Consumer DiscretionaryPersonal Goods
  • Price (CNY)32.55
  • Today's Change-0.45 / -1.36%
  • Shares traded2.94m
  • 1 Year change+2.04%
  • Beta1.2039
Data delayed at least 15 minutes, as of Feb 06 2026.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Guangdong Marubi Biotechnology Co Ltd is a China-based company principally engaged in the research, design, production, and sales of various cosmetics and related services. The Company’s products mainly include eye care products, skin cleansing products, skincare products, and beauty products. The Company's main brands include Marubi, Chunji, and Lianhuo. The Company mainly operates its businesses in the domestic market.

  • Revenue in CNY (TTM)3.47bn
  • Net income in CNY346.72m
  • Incorporated2002
  • Employees1.19k
  • Location
    Guangdong Marubi Biotechnology Co LtdNo.11 Xicun RoadZhujiang New City, Tianhe DistrictGUANGZHOU 510308ChinaCHN
  • Phone+86 2 066378685
  • Fax+86 2 066378600
  • Websitehttps://www.marubi.cn/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Hangzhou Haoyue Personal Care Co Ltd3.61bn296.42m6.82bn1.76k23.032.01--1.891.381.3816.7915.740.73236.4512.942,050,366.006.0211.538.3615.2829.7627.908.2216.351.26--0.074535.006.258.44-11.654.2116.00--
Guangdong Marubi Biotechnology Co Ltd3.47bn346.72m13.23bn1.19k38.173.98--3.820.86460.86468.658.290.74723.9882.732,926,428.007.537.3310.369.4072.8968.7710.0714.261.61--0.145255.5333.4410.5231.69-7.88118.0313.97
Shanghai Jahwa United Co Ltd6.16bn-590.47m15.00bn4.31k--2.13--2.43-0.8912-0.89129.2810.490.56793.627.891,429,630.00-5.442.10-7.412.8559.6557.80-9.583.581.57--0.082256.20-13.93-5.65-266.60---12.25-34.56
Data as of Feb 06 2026. Currency figures normalised to Guangdong Marubi Biotechnology Co Ltd's reporting currency: Chinese Yuan Renminbi CNY

Institutional shareholders

5.27%Per cent of shares held by top holders
HolderShares% Held
Fullgoal Fund Management Co., Ltd.as of 30 Jun 202511.51m2.87%
Bank of Communications Schroder Fund Management Co., Ltd.as of 30 Jun 20252.48m0.62%
HFT Investment Management Co., Ltd.as of 30 Jun 20252.37m0.59%
New China Fund Management Co., Ltd.as of 30 Jun 2025991.40k0.25%
China Southern Asset Management Co., Ltd.as of 30 Jun 2025943.00k0.24%
ICBC UBS Asset Management Co. Ltd.as of 30 Jun 2025799.89k0.20%
The Vanguard Group, Inc.as of 07 Jan 2026715.42k0.18%
China Asset Management Co., Ltd.as of 30 Jun 2025521.10k0.13%
China Universal Asset Management Co., Ltd.as of 30 Jun 2025427.00k0.11%
GF Fund Management Co., Ltd.as of 30 Jun 2025388.80k0.10%
More ▼
Data from 30 Jun 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.